N/A
Completed N=1,395
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
Source: ClinicalTrials.gov NCT06680206 ↗Enrolled (actual)
1,395
Serious AEs
—
Results posted
Jan 2026
Primary outcomePrimary: Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) — 74; 682; 61; 578 Participants — p==0.928
Summary
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007).
All data from the NHWS are reported by respondents, who are recruited through an existing, general-purpose, web-based, consumer panel via opt-in e-mails, co-registration with panel partners, e-newsletter campaigns, banner placements, and affiliate networks. All respondents explicitly agree to be a panel member, register with the panel through a unique e-mail address, and complete an in-depth demographic registration profile.
This analysis will focus on respondents who self-report having migraine diagnosed by a physician. Individuals who use rimegepant for acute treatment of migraine will be compared with those who use triptans for acute treatment of migraine. Outcomes of interest include treatment satisfaction, healthcare resource utilization (HCRU), quality of life (QoL), work productivity loss, and migraine-specific disability outcomes.
Inverse probability of treatment weighting (IPTW) will be used to adjust for differences that may exist between rimegepant and triptan users prior to comparing outcomes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) |
74; 682; 61; 578; 0; 0 | =0.928 |
| PRIMARY Number of Participants According to Migraine Treatment Type (Acute or Prevention) |
0; 837; 0; 0; 135; 423 | <0.001 sig |
| PRIMARY Total Number of Acute Migraine Agent Drug Classes Used |
2.1; 2.2 | =0.895 |
| PRIMARY Number of Participants According to Number of Acute Migraine Agent Drug Classes Used |
51; 431; 84; 829; 40; 406 | =0.463 |
| PRIMARY Total Number of Prevention Migraine Agent Drug Classes Used |
1.5; 0.5 | <0.001 sig |
| PRIMARY Number of Participants According to Number of Prevention Migraine Agent Drug Classes Used |
79; 297; 56; 126; 12; 25 | <0.001 sig |
| PRIMARY Number of Participants According to Current Migraine Treatments |
135; 0; 135; 1259; 0; 1260 | <0.001 sig |
| PRIMARY Number of Participants According to Treatment Satisfaction of Migraine Drug Class |
3; 97; 3; 45; 6; 92 | =0.030 sig |
| PRIMARY Number of Participants According to Current Migraine Treatments on OTC Class |
34; 198; 28; 221; 32; 320 | =0.011 sig |
| PRIMARY Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only) |
3; 13; 2; 3; 6; 13 | =0.050 |
| PRIMARY Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans |
1; 74; 1; 46; 4; 69 | =0.002 sig |
| PRIMARY Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Primary Analysis |
38.2; 37.1; 39.5; 39.8; 37.2; 36.7 | =0.308 |
| PRIMARY European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Index Score - Primary Analysis |
0.7; 0.7 | =0.372 |
| PRIMARY EQ-5D-5L Visual Analog Scale (VAS) Score - Primary Analysis |
66.5; 66.8 | =0.878 |
| PRIMARY Percentage of Work Time Missed in Past 7 Days Based on Work Productivity and Activity Impairment - General Health (WPAI-GH) Questionnaire- Primary Analysis |
7.1; 9.6 | =0.25 |
| PRIMARY Percentage Impairment Experienced While at Work in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis |
29.4; 27.6 | =0.582 |
| PRIMARY Percentage Overall Work Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis |
31.6; 31.1 | =0.898 |
| PRIMARY Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis |
41.3; 37.6; 31.8; 31.1; 48.8; 41.6 | =0.157 |
| PRIMARY Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis |
32.1; 26.8; 2.0; 2.1; 6.8; 4.9 | =0.146 |
| PRIMARY Number of Participants According to MIDAS Grade- Primary Analysis |
36; 363; 20; 138; 25; 238 | =0.601 |
| PRIMARY Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Primary Analysis |
36; 334 | =1 |
| PRIMARY Number of ER Visits in Past 6 Months- Primary Analysis |
0.5; 0.5 | 0.688 |
| PRIMARY Number of Participants With Hospitalizations in Past 6 Months- Primary Analysis |
15; 147 | =0.96 |
| PRIMARY Mean Number of Hospitalizations in Past 6 Months - Primary Analysis |
1.5; 2.5 | =0.115 |
| PRIMARY Number of Participants With Family Practitioner Visits in Past 6 Months- Primary Analysis |
102; 979 | =0.758 |
| PRIMARY Mean Number of Family Practitioner Visits in Past 6 Months- Primary Analysis |
2; 2 | =0.616 |
| PRIMARY Number of Participants With Cardiologist Visits in Past 6 Month- Primary Analysis |
21; 130 | =0.086 |
| PRIMARY Mean Number of Cardiologist Visits in Past 6 Months- Primary Analysis |
1.6; 1.8 | 0.528 |
| PRIMARY Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis |
72; 374 | <0.001 sig |
| PRIMARY Mean Number of Neurologist Visits in Past 6 Months- Primary Analysis |
2.6; 2 | 0.395 |
| PRIMARY Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis |
132; 1228 | =1 |
| PRIMARY Mean Number of Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis |
9.5; 7.8 | =0.08 |
| SECONDARY Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Sensitivity Analysis. |
39.1; 38.1; 40.6; 41.2; 38.3; 38 | =0.426 |
| SECONDARY European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Index Score- Sensitivity Analysis |
0.8; 0.7 | =0.189 |
| SECONDARY EQ-5D-5L Visual Analog Scale (VAS) Score- Sensitivity Analysis |
69.6; 68.9 | =0.727 |
| SECONDARY Percentage of Work Time Missed in Past 7 Days Based on Work Productivity and Activity Impairment - General Health (WPAI-GH) Questionnaire- Sensitivity Analysis |
6.4; 8.8 | =0.237 |
| SECONDARY Percentage Impairment Experienced While at Work in Past 7 Days Based on WPAI-GH Questionnaire-Sensitivity Analysis |
28.1; 25 | =0.401 |
| SECONDARY Percentage Overall Work Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Sensitivity Analysis |
30.4; 28.4 | =0.609 |
| SECONDARY Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Sensitivity Analysis |
37.6; 34.4; 30.6; 28.3; 44.4; 38.7 | =0.265 |
| SECONDARY Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis |
25.6; 21.6; 1.9; 1.8; 4.9; 4.1 | =0.266 |
| SECONDARY Number of Participants According to MIDAS Grade - Sensitivity Analysis |
29; 398; 17; 159; 23; 270 | =0.675 |
| SECONDARY Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Sensitivity Analysis |
27; 301 | =0.651 |
| SECONDARY Number of ER Visits in Past 6 Months- Sensitivity Analysis |
1.4; 1.8 | =0.004 sig |
| SECONDARY Number of Participants With Hospitalizations in Past 6 Months- Sensitivity Analysis |
11; 111 | =0.477 |
| SECONDARY Mean Number of Hospitalizations in Past 6 Months- Sensitivity Analysis |
1.2; 1.8 | =0.002 sig |
| SECONDARY Number of Participants With Family Practitioner Visits in Past 6 Months- Sensitivity Analysis |
76; 976 | =0.555 |
| SECONDARY Mean Number of Family Practitioner Visits in Past 6 Months- Sensitivity Analysis |
1.9; 2 | =0.371 |
| SECONDARY Number of Participants With Cardiologist Visits in Past 6 Months- Sensitivity Analysis |
14; 137 | =0.501 |
| SECONDARY Mean Number of Cardiologist Visits in Past 6 Months- Sensitivity Analysis |
1.3; 1.7 | =0.014 sig |
| SECONDARY Number of Participants With Neurologist Visits in Past 6 Months- Sensitivity Analysis |
57; 358 | <0.001 sig |
| SECONDARY Mean Number of Neurologist Visits in Past 6 Months- Sensitivity Analysis |
2.6; 1.9 | =0.392 |
| SECONDARY Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Sensitivity Analysis |
101; 1227 | =1 |
| SECONDARY Mean Number of Traditional Healthcare Provider Visits in Past 6 Months- Sensitivity Analysis |
9.2; 7.7 | =0.143 |
Eligibility Criteria
Inclusion Criteria
- Participated in 2023 NHWS in the US
- Consented to the anonymous use of their data for research purpose
- Aged 18 or older
- Self-reported a diagnosis of migraine by physician
- Currently on rimegepant or triptan (via oral route) at the time of the survey
Exclusion Criteria
- Currently on both rimegepant and triptans at the time of the survey
Data sourced from ClinicalTrials.gov (NCT06680206). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.